White Paper | Assessing Contribution Of Effect (COE) In Oncology Combination Therapies Lessons Learned To Inform And Optimize Future Registrational Trial Designs
Peer Review | Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies
Public Comment | Considerations for Generating Clinical Evidence From Oncology Multiregional Clinical Development Programs; Draft Guidance for Industry
White Paper | 2024 Annual Meeting | Pragmatism in Postmarket Trials
White Paper | 2024 Annual Meeting | Framework for Integrating Change in ctDNA Levels in Advanced Cancer Clinical Trials to Support Meta-analyses for Intermediate Endpoint Validation
Peer Review | Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology
RFI | Enhancing Adoption of Innovative Clinical Trial Approaches
Public Comment | Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
Poster | DIA 2024 | An Evaluation of PMRCs for Assessing Data in Racial and Ethnic Populations Underrepresented in Pivotal Trials Supporting Novel Oncology Approvals 2012-2023